[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"china\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:china":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100436519","screening-of-susceptibility-genes-for-apap-induced-drug-induced-liver-injury-in-chinese-population-a-case-control-study-100436519",false,"NCT04964310","Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study","Pharmacogenomics of APAP Induced DILI in Chinese Population.","PAIN","Inclusion criteria：\n\n* A clear history of acetaminophen (or acetaminophen-containing drugs) ingestion.\n* Plasma and\u002For urine testing for acetaminophen components if history of ingestion is unclear.\n* Monitoring of Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU\u002FL at any time after APAP administration and Roussel Uclaf Causality Assessment Method(RUCAM) score \\> 6\n* Age ≥ 14 years old\n* The subject or guardian agrees to participate in this project and signs an informed consent form.\n\nExclusion criteria：\n\n* The use of drugs for which frequency of adverse reactions to liver damage is defined as \"common or very common\" (≥1%) in the instructions.\n* Concurrent use of herbs that are clearly susceptible to liver damage (see list of definitions in the Annex).\n* Have a known definite cause of liver damage: active viral hepatitis; alcoholic liver disease; autoimmune liver disease; primary or secondary liver tumors; and other underlying liver disease that has affected liver function.\n* Those who fail to provide complete general information and clinical information.\n* Subjects or guardians who do not agree to see this project do not sign the informed consent form.","ALL","14 Years",{"count":20,"type":21},339,"ESTIMATED","OBSERVATIONAL","Acetaminophen (APAP) is the most commonly used NSAIDS in clinic, and it is also a common cause of drug-induced liver injury (DILI). In 2012, the proportion of DILI caused by APAP in the United States was 51%, while in Asia, it was only 7.10%. Previously, a small cohort study in the United States screened for some of the susceptibility genes for DILI due to APAP by the Genome wide association study (GWAS) method. However, the genetic susceptibility loci based on the US cohort were not applicable to the Chinese population. Therefore, we make a study design include Chinese population who ingested APAP and divided them into case group and control group according to the occurrence of DILI. We hope to be able to find the root of differences at the genetic level and explore new pathogenic mechanisms.",[25,26,27,28],"Acetaminophen","Drug-Induced Liver Injury","Pharmacogenetics","China",[25,26,27,28,30,31],"Case-Control Studies","candidate gene","RECRUITING","2025-02-24",{"date":35,"type":36},"2025-02-26","ACTUAL",{"date":38,"type":36},"2020-08-31",{"date":40,"type":21},"2026-12-31",{"name":42,"class":43},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100537321","protein-molecular-characteristics-and-prognosis-of-cervical-neuroendocrine-tumors-100537321","NCT06276309","Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors","Inclusion Criteria:\n\n1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology\n2. Clinical data were complete\n\nExclusion Criteria:\n\n1. Patients who are not being treated in our hospital\n2. Patients with lack of follow-up data, unable to obtain survival information\n3. Patients call to refuse to participate in this project\n4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination","FEMALE",{"count":53,"type":21},300,"The clinical diagnosis and treatment data of 300 cases of cervical neuroendocrine tumors were collected, including age, preoperative biopsy pathology results, postoperative histopathological results, TCT results, and colposcopy biopsy pathology results. At the same time, paraffin tissue specimens (remaining specimens after pathological diagnosis) from 100 cases of cervical neuroendocrine tumors from multiple centers across the country were collected to establish a cervical neuroendocrine tumor data follow-up database. Protein concentration and omics analysis were performed on the data results, to evaluate the molecular characteristics and prognosis of cervical neuroendocrine tumor proteins, and to preliminarily explore its clinical application value.",[56,28,57,58,59],"Neuroendocrine Neoplasm","Women","Cervical Cancer","Cervical Lesion","2024-09-12",{"date":62,"type":36},"2024-09-19",{"date":64,"type":36},"2024-02-01",{"date":66,"type":21},"2025-02-28",{"name":68,"class":43},"Fujian Maternity and Child Health Hospital",9]